Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 - 2025
The "Pharmacovigilance Market by Clinical Trial Phase, by Service Provider, by Method, and by End-User: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.
The report covers a forecast and an analysis of the pharmacovigilance market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Billion).
The study includes the drivers and restraints of the pharmacovigilance market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the pharmacovigilance market on a global level.
In order to give the users of this report a comprehensive view of the pharmacovigilance market, we have included a competitive landscape and an analysis of Porter's Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, product, and regional expansion of major participants involved in the market.
The study provides a decisive view on the pharmacovigilance market by segmenting it on the basis of clinical trial phase, service provider, method, end-user, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further classification into major countries including the U.S., UK, Germany, France, China, Japan, India, Brazil, etc.
Some key players in the global pharmacovigilance market include as F. Hoffmann-La Roche, Cognizant, Pharmaceutical Clinical Trial Phase Development, Bristol-Myers Squibb, Covance, ICON, Accenture, Pfizer, Clinquest Group, Novartis International, GlaxoSmithKline, PAREXEL International, iGATE Corporation, iMEDGlobal Corporation, and inVentiv Health.
Market Dynamics
Drivers
- Increasing Consumption of Drugs Fuels the Continuous Drug Event Monitoring Demand
- The Rising Adoption of Outsourcing Services
Restraints
- High Risk Associated With Data Security in Pharmacovigilance Outsourcing Opportunities
- Huge Scope for the Rapid Growth of Pharmacovigilance Market in Emerging Economies
This report segments the global pharmacovigilance market as follows:
Clinical Trial Phase Analysis
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Phase IV
Service Provider Analysis
- In-House
- Contract Outsourcing
Method Analysis
- Spontaneous Reporting
- Intensified ADR Reporting
- Targeted Spontaneous Reporting
- Cohort Event Monitoring
- EHR Mining
End-user Analysis
- Hospitals
- Research Organizations
- Industries
Companies Profiled
- F. Hoffmann-La Roche
- Cognizant
- Pharmaceutical Clinical Trial Phase Development
- Bristol-Myers Squibb
- Covance
- ICON
- Accenture
- Pfizer
- Clinquest Group
- Novartis International
- GlaxoSmithKline
- PAREXEL International
- iGATE Corporation
- iMEDGlobal Corporation
- inVentiv Health
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
